Lasmiditan is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F.1 Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential.2 Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications.
1.Nelson, D.L., Phebus, L.A., Johnson, K.W., et al.Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditanCephalalgia30(10)1159-1169(2010) 2.Wilbraham, D., Berg, P.H., Tsai, M., et al.Abuse potential of lasmiditan: A phase 1 randomized, placebo- and alprazolam-controlled crossover studyJ. Clin. Pharmacol.(2019)